GlassScriptPhysician profile
Jesse M Pines
NPI 1891742953
$350,017.85
in general payments reported to CMS, 2019-2025
14 companies · $40K in 2025
The $40K reported for 2025 was more than what 99% of Integrative Medicine providers received nationally (typical 2025 total: $57.65).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $22K · 2021: $44K · 2022: $86K · 2023: $62K · 2024: $51K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Travel and Lodging: $18K · Food and Beverage: $3,321 · Consulting Fee: $1,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,305.00 |
| Travel and Lodging | $18,171.52 |
| Food and Beverage | $3,321.08 |
| Consulting Fee | $1,685.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $284,158.19 | 2019-2025 | Kcentra |
| Abbott Laboratories | $30,795.14 | 2020-2025 | I-Stat |
| Novo Nordisk INC | $13,860.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,177.03 | 2022 | |
| Eagle Pharmaceuticals, INC. | $4,385.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $3,993.96 | 2022 | |
| Medtronic, INC. | $1,740.00 | 2022 | |
| Beckman Coulter, INC. | $1,575.00 | 2019-2021 | |
| Medtronic Vascular, INC. | $1,237.50 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $1,185.00 | 2023 | Seglentis |
| Orion Corporation | $500.00 | 2025 | |
| Baxter Healthcare | $350.00 | 2019 | |
| Tersera Therapeutics LLC | $60.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Pines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.